Caddie Laberiano-Fernandez
Overview
Explore the profile of Caddie Laberiano-Fernandez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
62
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Laberiano-Fernandez C, Gan Q, Wang S, Tamegnon A, Wistuba I, Yoon E, et al.
J Am Soc Cytopathol
. 2024 Mar;
13(3):161-173.
PMID: 38519275
Introduction: Malignant pleural effusion (MPE) is a frequent complication of advanced malignancies. In this pilot study, we characterized the immune landscapes of MPEs, compared them to their primary tumor (PT)...
2.
Parra E, Zhang J, Duose D, Gonzalez-Kozlova E, Redman M, Chen H, et al.
Clin Cancer Res
. 2024 Jan;
30(8):1655-1668.
PMID: 38277235
Purpose: Identifying molecular and immune features to guide immune checkpoint inhibitor (ICI)-based regimens remains an unmet clinical need. Experimental Design: Tissue and longitudinal blood specimens from phase III trial S1400I...
3.
Laberiano-Fernandez C, Baldavira C, Machado-Rugolo J, Tamegnon A, Pandurengan R, AbSaber A, et al.
Cancers (Basel)
. 2023 Nov;
15(21).
PMID: 37958292
Background: Several tumor-associated macrophages (TAMs) have shown promise as prognosticators in cancer. Our aim was to validate the importance of TAMs in malignant pleural mesothelioma (MPM) using a two-stage design....
4.
Karam J, Msaouel P, Haymaker C, Matin S, Campbell M, Zurita A, et al.
Nat Commun
. 2023 May;
14(1):2684.
PMID: 37164948
Sitravatinib is an immunomodulatory tyrosine kinase inhibitor that can augment responses when combined with programmed death-1 inhibitors such as nivolumab. We report a single-arm, interventional, phase 2 study of neoadjuvant...
5.
Laberiano-Fernandez C, Lujan J, de Carvalho Dornelas B, Benites M, Quispe P, Vasquez V, et al.
Ecancermedicalscience
. 2023 Feb;
16:1462.
PMID: 36819804
The seventh session of the Oncological Pathology Conference (JoPaO) entitled 'Pathological Anatomy in the context of the National Cancer Law: An overview of the Latin American experience', was held virtually...
6.
Johnson B, Haymaker C, Parra E, Solis Soto L, Wang X, Thomas J, et al.
J Immunother Cancer
. 2022 Aug;
10(8).
PMID: 36007963
Background: Monotherapy with immune checkpoint blockade is ineffective for patients (pts) with microsatellite stable (MSS) metastatic colorectal cancer (mCRC). This study investigates whether the combination of trametinib (T) with durvalumab...
7.
Rojas F, Hernandez S, Lazcano R, Laberiano-Fernandez C, Parra E
Front Oncol
. 2022 Jul;
12:889886.
PMID: 35832550
A robust understanding of the tumor immune environment has important implications for cancer diagnosis, prognosis, research, and immunotherapy. Traditionally, immunohistochemistry (IHC) has been regarded as the standard method for detecting...
8.
Sun B, Laberiano-Fernandez C, Salazar-Alejo R, Zhang J, Solorzano Rendon J, Lee J, et al.
Pathobiology
. 2022 May;
90(1):1-12.
PMID: 35609532
Introduction: Representative regions of interest (ROIs) analysis from the whole slide images (WSI) are currently being used to study immune markers by multiplex immunofluorescence (mIF) and single immunohistochemistry (IHC). However,...
9.
Laberiano-Fernandez C, Hernandez-Ruiz S, Rojas F, Parra E
Front Mol Biosci
. 2021 Sep;
8:660202.
PMID: 34532339
Multiplex immunofluorescence (mIF) tyramide signal amplification is a new and useful tool for the study of cancer that combines the staining of multiple markers in a single slide. Several technical...